Zoetis (ZTS) 주식 개요
는 미국 및 전 세계 동물 건강 산업을 위한 의약품, 백신, 진단 제품 및 서비스, 바이오 디바이스, 유전자 검사, 정밀 동물 건강 솔루션의 발견, 개발, 제조, 상용화에 관여합니다. 자세히 보기
ZTS Community Fair Values
Create NarrativeSee what 262 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Zoetis Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$76.68 |
| 52주 최고가 | US$160.48 |
| 52주 최저가 | US$71.00 |
| 베타 | 0.73 |
| 1개월 변동 | 0.63% |
| 3개월 변동 | -4.23% |
| 1년 변동 | -51.08% |
| 3년 변동 | -58.38% |
| 5년 변동 | -62.49% |
| IPO 이후 변동 | 147.28% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Aug 19
ZTS: Reset Expectations And Product Stabilization Will Drive Long-Term Premium Recovery
Analysts have reduced the Zoetis fair value estimate from $160 to about $149, reflecting lower Street price targets and updated expectations for margins, competitive pressures, and slightly softer revenue growth assumptions. Analyst Commentary Street research on Zoetis over recent months has centered on recalibrated price targets, shifting ratings and concern around key product trends.Seeking Alpha • Aug 14
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Summary Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt. I rate ZTS a Buy, as the risk/reward now favors value and dividend investors willing to tolerate near-term volatility and ongoing competitive headwinds. Read the full article on Seeking AlphaRecent updates
내러티브 업데이트 • Aug 19
ZTS: Reset Expectations And Product Stabilization Will Drive Long-Term Premium Recovery
Analysts have reduced the Zoetis fair value estimate from $160 to about $149, reflecting lower Street price targets and updated expectations for margins, competitive pressures, and slightly softer revenue growth assumptions. Analyst Commentary Street research on Zoetis over recent months has centered on recalibrated price targets, shifting ratings and concern around key product trends.Seeking Alpha • Aug 14
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Summary Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt. I rate ZTS a Buy, as the risk/reward now favors value and dividend investors willing to tolerate near-term volatility and ongoing competitive headwinds. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 05
ZTS: Future Therapies And Legal Risks Will Shape Confidence Reset
The Zoetis analyst price target has been reduced by $10 to $80. Analysts attribute this change to lower sector valuations, softer trends in veterinary clinic visits, and rising competitive and pricing pressures highlighted across recent research updates.
내러티브 업데이트 • Jul 22
ZTS: Premium Pet Health Portfolio Will Support Post Lawsuit And Guidance Reset
The analyst price target for Zoetis has been lowered, with the model fair value estimate moving from about $124.59 to $114.76, as analysts temper revenue growth assumptions while slightly improving profit margin and applying a lower future P/E multiple in response to a broad series of recent target cuts and more cautious commentary following Q1 results. Analyst Commentary Recent research on Zoetis shows a clear reset in expectations, with most analysts cutting price targets and recalibrating models after a difficult Q1 and updated guidance.
새로운 내러티브 • Jul 20
Wall Street Shock vs. Clinical Ground Truth — Is Zoetis a Value Trap or a Generational Mispricing?
Zoetis may not always look like the most high-tech, flashy ticker on Wall Street, but as a practicing veterinarian, my hands-on clinical experience tells a very different story. Sixteen years ago, when I first earned my veterinary license, the very first product I administered was Zoetis’ Vanguard vaccine.내러티브 업데이트 • Jul 08
ZTS: Depressed Sentiment Will Set Up Long-Term Premium Portfolio Recovery
The analyst price target for Zoetis has been revised down from about $184 to $160. This reflects lower modeled revenue growth, a slightly higher discount rate, and reduced future P/E assumptions, which are partly tied to recent sector wide target cuts and concerns around key products and consumer trade down.내러티브 업데이트 • Jun 24
ZTS: Future Pipeline And New Therapies Will Restore Confidence
Zoetis' analyst-derived fair value has been reset from $127.00 to $90.00 as analysts factor in weaker growth assumptions, a lower future P/E, and softer margin expectations following recent price target cuts and downgrades tied to investor confidence and competitive pressures. Analyst Commentary Recent research on Zoetis points to a more cautious mood, with several bearish analysts focusing on valuation pressure, softer execution and questions around the strength of future growth.분석 기사 • Jun 20
Zoetis (ZTS) Stock Could Be 15.3% Undervalued After Class Action Lawsuits
Zoetis (ZTS) is back in focus after a series of securities class action lawsuits accused the company of misleading investors about weakening demand, safety concerns, and market share losses in its key companion animal products. See our latest analysis for Zoetis. At a share price of $78.71, Zoetis has seen pressure build over the past few months, with a 90 day share price return that declined 31.95% and a 1 year total shareholder return that declined 49.14%. Repeated class action...내러티브 업데이트 • Jun 10
ZTS: Premium Pet Health Portfolio Will Support Post Selloff Earnings Reset
Analysts have trimmed Zoetis' average price target by roughly $30 to $40 to around the low $100s. This reflects recent target cuts from firms citing softer Q1 results, intensifying competition, and a sharp pullback in the stock that has weighed on investor confidence.내러티브 업데이트 • May 26
ZTS: Premium Pet Health Portfolio Will Support Reset Earnings Path Forward
Zoetis' analyst fair value estimate has been reset from $151.00 to about $124.59 as analysts trim price targets after a difficult Q1, rising competitive pressures, and signs that premium pricing is meeting more cautious consumer demand, despite longer term guidance implying improvement. Analyst Commentary Recent research points to a reset in expectations for Zoetis, with target prices broadly trimmed as analysts rework their models around the latest Q1 update, rising competition, and more cautious consumer behavior toward premium products.
새로운 내러티브 • May 26
Zoetis down -50% over the past year
World's leading animal pharma company at 13x PE with 9% EPS growth Occasionally something crosses my eye which screens well, but after some work is done it isn’t interesting enough to warrant writing about it as a paid article. Zoetis is one such stock.내러티브 업데이트 • May 03
ZTS: Share Repurchases And Capital Discipline Will Support Medium-Term Upside
Analysts have modestly trimmed their Zoetis fair value estimate by about $3 to $184, reflecting mixed updates to revenue growth, margins, and long term P/E assumptions after recent shifts in price targets and ratings across the Street. Analyst Commentary Recent research updates on Zoetis reflect a mix of reduced price targets, a downgrade on growth concerns, and fresh bullish coverage.내러티브 업데이트 • Apr 19
ZTS: Fair View Weighs Organic Growth Concerns Against Pipeline Execution Risk
Analysts have trimmed the Zoetis fair value estimate by $3 to $127, reflecting a mix of cautious views around organic growth and slightly adjusted assumptions for future P/E, revenue growth, and profitability, even as some firms maintain a bullish stance on the stock. Analyst Commentary Recent Street research around Zoetis shows a split tape, with several bearish analysts focusing on weaker organic growth trends and execution risk, even as others remain constructive on the long term story.내러티브 업데이트 • Apr 04
ZTS: Share Repurchases And Execution Recovery Will Support Medium-Term Upside
Analyst targets on Zoetis have shifted modestly, with a small net reduction in the Street price target in dollar terms as some analysts cite concerns about organic growth and an innovation "air pocket," even as others make minor upward adjustments. Analyst Commentary Recent Street research on Zoetis reflects a split view, with some analysts emphasizing concerns around organic growth and an innovation air pocket, while others are adjusting targets in a more constructive way.내러티브 업데이트 • Mar 21
ZTS: Future OA Pain Launch And Buybacks Will Support Medium-Term Upside
Narrative Update The updated analyst price target for Zoetis moves from about $197.51 to $187.59, reflecting analysts' mixed views. Some cite softer organic growth and an innovation "air pocket," while others make smaller price target adjustments.내러티브 업데이트 • Mar 06
ZTS: Fair View Balances Growth Concerns With Innovation Air Pocket Risk
Zoetis's analyst price target holds steady at $130, as analysts balance concerns about organic growth and an innovation "air pocket" with stable margin expectations and a lower future P/E assumption. Analyst Commentary Recent Street research on Zoetis points to a more cautious tone, with several bearish analysts questioning the near term growth setup and how that lines up with the current valuation.내러티브 업데이트 • Feb 20
ZTS: Future Pet Osteoarthritis Pipeline Will Support Premium Multiple Potential
Zoetis' analyst fair value estimate has been reset from $158.22 to $151.00, as analysts balance recent price target changes and a slightly lower assumed future P/E multiple against broadly steady growth and margin assumptions. Analyst Commentary Recent Street research on Zoetis points to a mixed setup, with some analysts seeing support for the current valuation and others focusing on execution risk and the product pipeline.내러티브 업데이트 • Feb 06
ZTS: Future OA Pain Launch Execution Will Drive Medium-Term Upside Potential
Analysts have trimmed their Zoetis fair value estimate from about US$200 to roughly US$197.51. This reflects recent price target cuts and more cautious views around product launch headwinds and competition, even as they still see solid margins and a premium P/E as part of the story.내러티브 업데이트 • Jan 22
ZTS: Fair Outlook Balances OA Pain Headwinds With New Antibody Approvals
Narrative update on Zoetis The analyst fair value estimate for Zoetis has been reset from US$153 to US$130 as analysts factor in slower expected revenue growth, a slightly higher discount rate, lower assumed future P/E multiples, and ongoing competitive and product launch headwinds highlighted in recent research. Analyst Commentary Recent research on Zoetis has tilted more cautious, with several bearish analysts resetting expectations around growth, execution, and what investors are willing to pay for the stock.내러티브 업데이트 • Jan 08
ZTS: Future Product Launches Will Offset Current Competition Pressures
Analysts have trimmed their price targets on Zoetis, reflecting a fair value move from about $170 to $158 as they factor in product launch headwinds, tougher competition in key franchises, and more cautious revenue expectations for 2025 and 2026. Analyst Commentary Recent Street research reflects a mixed but more cautious stance on Zoetis, with several firms trimming price targets and reassessing growth and competitive risks over the next few years.내러티브 업데이트 • Dec 15
ZTS: Execution In Animal Health Leadership Will Drive Medium-Term Upside Potential
Analysts have cut their fair value estimate for Zoetis by about $30,000,000,000 to roughly $200,000,000,000, reflecting expectations for slower mid decade revenue growth, modestly lower margins, and a less generous future earnings multiple amid increasing competitive and product launch headwinds. Analyst Commentary Recent Street research reflects a more balanced stance on Zoetis, with fair value expectations reset lower but many firms still highlighting the company as a structural leader in animal health.내러티브 업데이트 • Nov 30
ZTS: Earnings Will Recover As Competition Pressures Recent Product Launches
Zoetis's fair value target experienced a modest reduction to $169.96. Analysts highlighted competitive pressures and headwinds from recent product launches as key drivers for the change.내러티브 업데이트 • Nov 16
ZTS: Earnings Will Rebound As Volume Pressures Ease In 2026
Zoetis' analyst price target has been reduced from approximately $188 to $171 per share, as analysts cite tempered growth expectations and revised financial assumptions following recent quarterly updates. Analyst Commentary Following Zoetis' latest quarterly updates and subsequent guidance revision, analysts have updated their perspectives on the company's outlook.내러티브 업데이트 • Nov 01
ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters
Narrative Update: Zoetis Analyst Price Target Adjustment Analysts have modestly decreased their price target for Zoetis from $165 to $158, citing a more cautious outlook ahead of upcoming results. Analyst Commentary Analyst perspectives on Zoetis highlight both optimism regarding the company’s long-term fundamentals as well as heightened caution leading into upcoming earnings releases.내러티브 업데이트 • Oct 18
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $189.22 to $188.83, citing modest revisions to revenue growth estimates. They also noted a marginal increase in expected profit margins.내러티브 업데이트 • Oct 04
Companion Animal And Livestock Demand Will Unlock Future Opportunities
Analysts have slightly lowered their price target for Zoetis from $190.29 to $189.22, citing marginally softer revenue growth and profit margin expectations. What's in the News Zoetis received conditional FDA approval for Dectomax-CA1, the first and only injectable for preventing and treating infestations caused by New World screwworm larvae in cattle.주주 수익률
| ZTS | US Pharmaceuticals | US 시장 | |
|---|---|---|---|
| 7D | 4.3% | 6.0% | -0.8% |
| 1Y | -51.1% | 59.4% | 20.5% |
수익률 대 산업: ZTS은 지난 1년 동안 59.4%의 수익을 기록한 US Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: ZTS은 지난 1년 동안 20.5%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: ZTS는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ZTS의 주간 변동성(5%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2012 | 14,500 | Kristin Peck | www.zoetis.com |
는 미국 및 전 세계 동물 건강 산업을 위한 의약품, 백신, 진단 제품 및 서비스, 바이오 디바이스, 유전자 검사, 정밀 동물 건강 솔루션의 발견, 개발, 제조, 상용화에 종사하고 있습니다. 이 회사는 주로 개, 고양이, 말 등의 반려동물과 소, 돼지, 가금류, 어류, 양 등의 가축을 포함한 종에 걸쳐 제품을 상용화하고 있습니다. 또한 기생충, 백신, 피부과, 항감염제, 통증 및 진정제, 기타 의약품 및 동물 건강 진단도 제공합니다.
Zoetis Inc. 기초 지표 요약
| ZTS 기초 통계 | |
|---|---|
| 시가총액 | US$30.56b |
| 순이익 (TTM) | US$2.64b |
| 매출 (TTM) | US$9.53b |
12.0x
주가수익비율(P/E)3.3x
주가매출비율(P/S)ZTS는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ZTS 손익계산서 (TTM) | |
|---|---|
| 매출 | US$9.53b |
| 매출원가 | US$2.69b |
| 총이익 | US$6.83b |
| 기타 비용 | US$4.20b |
| 순이익 | US$2.64b |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 6.38 |
| 총이익률 | 71.74% |
| 순이익률 | 27.69% |
| 부채/자본 비율 | 288.0% |
ZTS의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Zoetis 배당 일정 | |
|---|---|
| 배당락일 | Jul 20 2026 |
| 배당 지급일 | Sep 01 2026 |
| 배당락일까지 남은 일수 | 32 days |
| 배당 지급일까지 남은 일수 | 11 days |
ZTS는 안정적으로 배당을 지급합니까?
ZTS 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/19 17:51 |
| 종가 | 2026/08/19 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Zoetis Inc.는 39명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Charles Butler | Barclays |
| Glen Santangelo | Barclays |